Preliminary analysis shows one complete response (CR) and two partial responses
Median progression-free survival (PFS) for Part A was 5.5 months (n=9), versus thehistorical control of 3.4 months,
Growing body of data provides strong evidence that Cantrixil is clinically active in thisvery late-stage patient population
Safety profile consistent with prior experience: most common adverse events weregastrointestinal in nature and low-grade
Australian lead investigator, Associate Professor Jermaine Coward, commented
“despite recent progress in ovarian cancer, there remains an urgent need for new therapies.
The Cantrixil phase I study was conducted in a very late-stage patient population, with few effective treatment options.
In that context, my colleagues and I consider these data to be extremely promising.”
Cantrixil has been able to shrink tumours and delay disease progression, demonstrating a clinically meaningful benefit
- Forums
- ASX - By Stock
- Ann: Cantrixil last patient visit
Preliminary analysis shows one complete response (CR) and two...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online